Researchers from Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd. and affiliated organizations have published preclinical data for the novel rearranged during transfection (RET) kinase inhibitor, FHND-5071.
Reninomas are rare renin-secreting kidney tumors, resulting from a neoplastic expansion of juxtaglomerular cells of the kidney, which are cells that regulate blood pressure via the secretion of renin. Based on previous research that has proposed a central role for NOTCH1 signaling in the regulation of renin secretion by juxtaglomerular cells, researchers from Wellcome Sanger Institute, University of Cambridge, and affiliated organizations aimed to investigate the role of NOTCH1 in reninoma.
Mission Bio Inc. released its Tapestri single-cell minimal residual disease (MRD) assay for acute myeloid leukemia (AML) on September 26, with the goal of enabling greater personalization of care for patients with blood cancers. The test can provide insights into the progression of AML and help identify targets for treatment in addition to identifying patients truly experiencing relapse as distinct from having pre-leukemic or precursor clones.
Several Insilico Medicine Inc. patents describe diacylglycerol kinase α (DGK-α, DGKA) inhibitors reported to be useful for the treatment of cancer and viral infection.
Sichuan Huiyu Pharmaceuticals Co. Ltd. and Sichuan Huiyu Seacross Pharma Technology Ltd. have jointly described new phosphatidylinositol 3-kinase (PI3K) and/or GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.
Researchers from the University of Minnesota and collaborators have synthesized and evaluated a novel series of antiproliferative benzofuran derivatives that led to the identification of [I] as the most potent candidate.
Pathios Therapeutics Ltd. has been awarded a £567,000 (~US$727,000) grant from the U.K. Government’s innovation agency, Innovate UK, that will enable the company to expand its development of novel small-molecule GPR65 inhibitors into the area of malignant brain tumors.
Researchers from Birla Institute of Technology & Science, Pilani and Jadavpur University have reported novel HDAC3 inhibitors as potential candidates for the treatment of breast cancer. Synthesis and optimization of a series of pyrazino-hydrazide-based HDAC3 inhibitors led to the characterization of compound [I] as the lead candidate with potent HDAC3 inhibitory activity (IC50=14 nM) and at least 121-fold selectivity.
Among all human papillomavirus (HPV) types described so far, the two most abundant – HPV16 and HPV18 – are responsible for 71% of all cervical cancers. The vaccines currently used are effective in preventing viral infection, but have no effect on already infected or maligned cells.
Researchers from Umm Al-Qura University and affiliated organizations have published details on the discovery and preclinical evaluation of anticancer candidates acting both as COX-2 inhibitors and tubulin-targeting agents.
RSS
